• Contact Us
  • Sign Up
  • TWITTER
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Microbiome Job Board

Microbiome Times

Finance

Boehringer Ingelheim and BiomX Collaborate to Discover IBD Microbiome Biomarkers

July 5, 2022 Microbiome Times

BiomX Inc. (NYSE American: PHGE) (“BiomX” or “Company”) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (“IBD”). BiomX is a clinical-stage microbiome company advancing novel natural and engineered phage […]

Finance

4D pharma Receives Notice of Delisting From Nasdaq

June 29, 2022 Microbiome Times

Source: 4D Pharma 4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced that on June 27, 2022, it received written […]

Finance

Vedanta Unveils State-of-the-Art Manufacturing Facility

June 29, 2022 Microbiome Times

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, […]

Finance

4D Pharma Update on Suspension of Trading in the Company’s ordinary shares

June 24, 2022 Microbiome Times

Source: 4D Pharma 4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the […]

Pharma & Human Health

Bacthera: Enabling the Live Biotherapeutic Industry

June 20, 2022 Microbiome Times

Bacthera tailor live biotherapeutic product services to meet your needs, whether you are an early start-up, a fully established biotech company, or part of a pharma company working with live biotherapeutic products. We offer a […]

Pharma & Human Health

Unprecedented case series advances promise of phage therapy

June 16, 2022 Microbiome Times

An international team of researchers, led by scientists at University of California San Diego School of Medicine and the University of Pittsburgh, report promising results from the largest case series yet of patients treated with […]

Pharma & Human Health

Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection

June 8, 2022 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The overall safety profile observed […]

Pharma & Human Health

Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages

June 6, 2022 Microbiome Times

Pherecydes Pharma (Paris:ALPHE) (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has been granted AAC Early Access Program approval by the […]

Pharma & Human Health

Ethical challenges in microbiome research

May 24, 2022 Microbiome Times

A human rights activist and a group of anthropologists and human biologists are casting a critical lens on the way that microbiome research is conducted with Indigenous peoples. While this isn’t the first time that […]

Pharma & Human Health

Phage therapy: A model to predict its efficacy against pathogenic bacteria

May 23, 2022 Microbiome Times

Antibiotic resistance represents a major public health challenge, associated with a high mortality rate. While bacteriophages – viruses that kill bacteria – could be a solution for fighting antibiotic-resistant pathogens, various obstacles stand in the […]

Pharma & Human Health

Researchers use virus to fight bacterial infection clearing way for life-saving lung transplant

May 17, 2022 Microbiome Times

For the first time, researchers have successfully used bacteriophages – viruses that kill bacteria – to treat an antibiotic-resistant mycobacterial lung infection, clearing the way for a young National Jewish Health patient with cystic fibrosis […]

Posts navigation

1 2 … 55 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview
    June 27, 2022
  • Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
    April 15, 2022
  • Did you miss Probiota Copenhagen 2022? Catch up now!
    April 12, 2022
  • A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology
    February 18, 2022
  • Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
    February 17, 2022
sign up

Sign up to the Microbiome Times newsletter